Table 5. Clinical trials of p38 inhibitors.
| Drug | Target | Condition or disease | Status | NCT number |
|---|---|---|---|---|
| ARRY-371797 | p38 | Ankylosing spondylitis | Phase 2 | NCT00811499 |
| ARRY-371797 | p38 | Dental pain | Phase 2 |
NCT00542035
NCT00663767 |
| ARRY-371797 | p38 | Healthy | Phase 1 | NCT00790049 |
| ARRY-371797 | p38 | LMNA-related dilated cardiomyopathy | Phase 2 |
NCT02351856
NCT02057341 |
| ARRY-371797 | p38 | Osteoarthritis of the knee | Phase 2 | NCT01366014 |
| ARRY-371798 | p38 | Rheumatoid arthritis | Phase 1 | NCT00729209 |
| ARRY-614 | p38 and
Tie2 |
Myelodysplastic syndromes | Phase 1 |
NCT01496495
NCT00916227 |
| AZD7624 | p38 | Corticosteroid-resistant asthma | Phase 2 | NCT02753764 |
| BIRB 796 BS | p38 | Healthy | Phase 1 | NCT02211170 |
| BMS-582949 | p38α | Rheumatoid arthritis | Phase 2 | NCT00605735 |
| BMS-582949 | p38α | Vascular diseases (atherosclerosis) | Phase 2 | NCT00570752 |
| CHF6297 | p38α | Chronic obstructive pulmonary
disease |
Phase 1/2 | NCT02815488 |
| Losmapimod
(GS856553) |
p38α/β | Acute coronary syndrome | Phase
1/2/3 |
NCT01756495
NCT02145468 NCT00910962 |
| Losmapimod
(GS856553) |
p38α/β | Chronic obstructive pulmonary
disease |
Phase 2 |
NCT00642148
NCT01541852 |
| Losmapimod
(GS856553) |
p38α/β | Depressive disorder, major | Phase 2 |
NCT00976560
NCT00569062 |
| Losmapimod
(GS856553) |
p38α/β | Glomerulosclerosis, focal segmental | Phase 2 | NCT02000440 |
| Losmapimod
(GS856553) |
p38α/β | Pain, neuropathic | Phase 2 |
NCT01110057
NCT00969059 |
| LY3007113 | p38 | Metastatic cancer | Phase 1 | NCT01463631 |
| Neflamapimod
(VX-745) |
p38α | Alzheimer’s disease | Phase 2 |
NCT03402659
NCT02423200 NCT02423122 |
| Neflamapimod
(VX-745) |
p38α | Dementia with Lewy bodies | Recruiting | NCT04001517 |
| P38 inhibitor
(4) |
p38 | Rheumatoid arthritis | Phase 2 |
NCT00303563
NCT00316771 |
| PF-03715455 | p38α | Asthma | Phase 2 | NCT02219048 |
| PF-03715455 | p38α | Chronic obstructive pulmonary
disease |
Phase 2 | NCT02366637 |
| PF-03715455 | p38α | Healthy | Phase 1 | NCT01226693 |
| PH-797804 | p38α/β | Rheumatoid arthritis | Phase 2 |
NCT00383188
NCT00620685 |
| Ralimetinib
(LY2228820) |
p38α/β | Adult glioblastoma | Phase 1/2 | NCT02364206 |
| Ralimetinib
(LY2228820) |
p38α/β | Advanced cancer | Phase 1 | NCT01393990 |
| Ralimetinib
(LY2228820) |
p38α/β | Epithelial ovarian cancer Fallopian
tube cancer Primary peritoneal cancer |
Phase 1/2 | NCT01663857 |
| Ralimetinib
(LY2228820) |
p38α/β | Postmenopausal metastatic breast
cancer |
Phase 2 | NCT02322853 |
| SB-681323 | p38 | Acute lung injury | Phase 2 | NCT00996840 |
| SB-681323 | p38 | Coronary heart disease | Phase 2 | NCT00291902 |
| SB-681323 | p38 | Chronic obstructive pulmonary
disease |
Phase 1/2 |
NCT00564746
NCT00144859 |
| SB-681323 | p38 | Pain, neuropathic | Phase 2 | NCT00390845 |
| SB-681323 | p38 | Rheumatoid arthritis Inflammation | Phase 1/2 |
NCT00419809
NCT00439881 NCT00134693 |
| Talmapimod
(SCIO-469) |
p38α | Bone marrow diseases
Myelodysplastic syndromes Hematologic diseases Bone marrow neoplasms |
Phase 2 | NCT00113893 |
| Talmapimod
(SCIO-469) |
p38α | Multiple myeloma | Phase 2 |
NCT00095680
NCT00087867 |
| Talmapimod
(SCIO-469) |
p38α | Rheumatoid arthritis | Phase 2 |
NCT00043732
NCT00089921 |
| VX-702 | p38α | Rheumatoid arthritis | Phase 2 |
NCT00395577
NCT00205478 |